210223-97-5

Usage

Chemical structure

Consists of an acetamide group, a phenylethyl group, and an amino group with a dimethoxyethyl substituent.

Salt form

Hydrochloride salt, making it water-soluble.

Classification

Quaternary ammonium compound.

Pharmaceutical applications

Water solubility allows for various uses in pharmaceuticals.

Research and drug development

Commonly used due to its potential therapeutic properties as an amide derivative.

Potential therapeutic activities

Analgesic, anesthetic, or anticonvulsant.

Mechanism of action

Subject to further investigation.

Therapeutic potential

Also subject to further investigation.

Upstream product

• 64-04-0 phenethylamine 
• 13156-95-1 2-chloro-N-phenethylacetamide 
• 22483-09-6 2,2-dimethoxyethylamine 

Downstream Products

• 61196-37-0 2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one 
• 99746-73-3 (S)-(-)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one 
• 55375-92-3 (R)-(-)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one 
• 135526-78-2 (-)-Praziquantel 
• 1240039-28-4 2-(4-fluorobenzyl)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one hydrochloride 

Relevant academic research and scientific papers

One-pot palladium-catalyzed racemization of (S)-praziquanamine: A key intermediate for the anthelmintic agent (R)-praziquantel

An one-pot palladium-catalyzed procedure for racemization of (S)-praziquanamine, which is the undesired enantiomer and produced during the resolution step for preparing the anthelmintic drug (R)-praziquantel, has been developed through dehydrogenation of

Design and synthesis of novel pyrazino[2,1-a]isoquinoline derivatives with potent antifungal activity

A series of novel pyrazino[2,1-a]isoquinoline compounds were designed, synthesized, and their antifungal activities in vitro were evaluated. The results showed that all of the title compounds exhibited antifungal activities. Most of them exhibited stronge

2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS

A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof (I) wherein R2 represents a hydrogen or the like; R3 represents methyl group or the like; R20 represents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; R4 represents hydrogen or the like; R5 represents hydrogen or the like; R6 represents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH2, oxygen atom, NH, or the like; any one or more of R5 and R6, R5 and R4, R6 and R4, X and R5, X and R4, X and R6, and R6 and R6 may combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).